<DOC>
	<DOCNO>NCT02140437</DOCNO>
	<brief_summary>This research design investigate whether addition fulvestrant 500mg anastrozole well anastrozole alone first-line endocrine therapy advance breast cancer .</brief_summary>
	<brief_title>Fulvestrant Combined Anastrozole Versus Anastrozole Luminal A-like Postmenopausal ABC</brief_title>
	<detailed_description>Anastrozole standard first-line endocrine treatment patient hormonal receptor positive advance breast cancer . It proven addition fulvestrant 250mg enhance PFS anastrozole monotherapy accord SWOG0226 study . However , optimal recommend dose fulvestrant patient advance breast cancer 500mg worldwide accord CONFIRM study . The investigator design research investigate whether high dose fulvestrant improve efficacy anastrozole monotherapy .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Fulvestrant</mesh_term>
	<mesh_term>Anastrozole</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Phenobarbital</mesh_term>
	<criteria>1 . Signed informed consent 2 . Histologically confirm breast cancer 3 . Luminal Alike breast cancer ( primary metastatic tumor ) , define : ERpositive , PRpositive ( &gt; 20 % ) , Her2 negative Ki67 &lt; 14 % . 4 . Advanced breast cancer eligible : Endocrine therapynaive patient locally advanced disease , suitable radical surgery radiotherapy ( decision make multidisciplinary breast cancer team ) . Prior firstline cytotoxic chemotherapy acceptable . Patients recurrent metastatic disease , receive adjuvant endocrine therapy 2 year longer stop adjuvant endocrine therapy . Patients disease progression firstline cytotoxic chemotherapy allow . 5 . At least one lesion ( measurable / nonmeasurable ) assess baseline , suitable repeat assessment CT and/or MRI . 6 . Postmenopausal woman , define one follow criterion ( define NCCN 's menopause definition ) : previous bilateral oophorectomy 60 year old old less 60 year old , amenorrheic 12 month long absence chemotherapy , tamoxifen , toremifene , ovarian suppression folliclestimulating hormone estradiol postmenopausal range . If take tamoxifen , toremifene age &lt; 60 , FSH E postmenopausal range 7 . ECOG 0 , 1 2 . 8 . Patients good compliance . 9 . Must able swallow tablet . 10 . Without significant gastrointestinal obstruction dysfunction absorption oral drug . 1 . Lifethreatening metastatic visceral disease , define extensive liver involvement degree brain leptomeningeal involvement ( past present ) symptomatic pulmonary lymphatic metastasis . If investigator believe respiratory function significantly impair due illness , patient scatter parenchymal metastasis qualify . 2 . Have receive systemic treatment firstline cytotoxic chemotherapy . 3 . Radiation therapy within 28 day prior randomization ( exception : radiotherapy control bone pain , complete randomization ) . 4 . Use anticancer therapy time ( except bisphosphonate ) . 5 . Previous endocrine treatment advance breast cancer . 6 . Current previous malignancy ( except breast cancer , basal cell squamous cell carcinoma skin adequate treatment , cervical carcinoma situ ) . 7 . Inadequate blood liver renal function within one week prior randomization : Platelets &lt; 80 × 10^9/L ; Total bilirubin &gt; 1.5 × ( ULRR ) ( patient Gilbert 's syndrome eligible ) ; ALT AST &gt; 2.5 × ULRR ( without liver metastasis ) &gt; 5 × ULRR ( liver metastasis ) . 8 . History hemorrhagic constitution ( e.g . disseminate intravascular coagulation , clot factor deficiency ) longterm anticoagulant therapy . 9 . Hypersensitivity history excipients castor oil fulvestrant anastrozole . 10 . Any severe coexist medical disorder , ie uncontrolled heart disease . 11 . Participation clinical trial / exposure investigational medication within 28 day randomization .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Fulvestrant</keyword>
	<keyword>Anastrozole</keyword>
	<keyword>Luminal A-like</keyword>
	<keyword>Postmenopausal</keyword>
	<keyword>Advanced breast cancer</keyword>
</DOC>